AlphAIalphai — Financial news for AI agents
benzinga.comJUL 93 min read$SPRY

What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY)

ARS Pharmaceuticals (NASDAQ:SPRY) announced a leadership change. Co-founder and CEO Richard Lowenthal stepped down as employee and officer effective July 6, 2026. Donn Casale, president, was appointed CEO and director effective July 7, 2026. William Blair and analyst Lachlan Hanbury-Brown discussed a more cautious neffy outlook, lowering Q2 neffy revenue to $26.4M and fair value to $21 from $31; SPRY was down 1.6% to $7.97.

Original reporting
benzinga.com
Published Jul 9, 2026, 6:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
What's Going on With ARS Pharma Stock Thursday? - ARS Pharmaceuticals (NASDAQ:SPRY) — source image
Source · benzinga.com
Decision brief

The 30-second read

$SPRYBearishMed
01

Why it matters

The combination of management change and analyst estimate reductions (peak penetration, prescriptions, Q2 revenue, and fair value) raises the probability of further expectation resets around Neffy demand and strategy.

02

Market read

Traders may reprice SPRY around Neffy demand expectations and management execution risk ahead of the Q2 earnings call.

03

What to watch

The article cites inventory build offsetting lower prescriptions, so near-term revenue may be less weak than prescriptions alone suggest; the Q2 call could also change the adoption narrative.

Relevance 7/10Novelty 6/10Timing: Ahead of the second-quarter earnings call, where additional Neffy strategy and outlook details are expected.

Background

ARS Pharma is navigating a Neffy launch that analysts say has not met earlier expectations, and it has now executed a CEO transition effective July 7, 2026.

Company-level read

Ticker impact

$SPRYBearishMedium confidence
Context

ARS Pharmaceuticals announced CEO/co-founder Richard Lowenthal stepping down and Donn Casale becoming CEO, plus William Blair cut estimates for Neffy.

Expected impact

Bias to downside or higher volatility until the Q2 earnings call clarifies Neffy strategy and demand trajectory.

Evidence & confidence

The article pairs a fresh executive transition with specific analyst estimate cuts (revenue, fair value, penetration, prescriptions), which typically pressures sentiment and expectations ahead of the next earnings call.

Market effects

Sector

Could affect sentiment across vaccine commercialization stories, especially for companies tied to Neffy-like launch execution and adoption curves.

Regional

Primarily US small/mid-cap biotech sentiment, with limited direct regional spillover implied.

Global

Limited global read-through; the catalyst is company-specific (Neffy commercialization and management transition).

Counterpoint

What could challenge this read

Casale’s appointment may be viewed as a commercialization-focused reset, and the “measured” base case could already be priced in if investors expected volatility around Neffy adoption.

Key entities

  • public_company
    SPRY

    ARS Pharmaceuticals, subject of the leadership transition and analyst estimate revisions tied to Neffy.

  • executive
    Richard Lowenthal

    Co-founder and CEO who stepped down effective July 6, 2026.

  • executive
    Donn Casale

    President appointed CEO and director effective July 7, 2026.

  • analyst_firm
    William Blair

    Issued a note discussing the abruptness of the CEO move and later estimate changes for Neffy.

  • analyst
    Lachlan Hanbury-Brown

    Analyst who lowered Neffy penetration and revised Q2 revenue and fair value estimates.

Read at source← All news

Related articles

AUG 22
$SPRYMedAI 8/10

ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript

ARS Pharma (SPRY) reported Q2 2026 U.S. net product revenue of $26.2M, with total market share reaching 5%, up from 2.5% YoY. Neffy's market share in targeted areas hit 8%, driven by 16,000+ unique prescribers. The company aims to expand into the CSU market and expects cash flow breakeven by late 2027. Total revenue was $33.7M, with operating expenses at $95.1M. ARS plans to reduce SG&A and R&D expenses by over 40% in the second half of 2026.

yahoo.com3 min
AUG 21
$SPRYMed

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share

ARS Pharmaceuticals (SPRY) reported Q2 2026 earnings, with Neffy's US market share doubling to 5% YoY. CEO Donn Casale outlined priorities including targeted commercial efforts and cost cuts. Revenue was $33.7M, with operating expenses at $95.1M. The company plans to reduce spending by over 40% in H2 2026 and aims for cash flow breakeven by late 2027. Short interest is high at 31.17% of the float.

insidermonkey.com2 min
AUG 18
$SPRYMedAI 8/10

ARS Pharma Refocuses Strategy As Q2 Revenue Hits $33.7M

ARS Pharmaceuticals (SPRY) reported Q2 2026 revenue of $33.7M, up from $15.7M a year earlier, driven by $26.2M U.S. net product revenue from neffy. Net loss widened to $62.3M ($0.63/share). The company cut broad consumer ads, targeted high-volume prescribers, appointed Meg Smith CCO, and expects H2 2026 SG&A and R&D of $114M-$126M.

rttnews.com6 min
AUG 14
$SPRYMed

ARS Pharmaceuticals Q2 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) said it expanded its field sales force and will target high-value prescribers, noting neffy has about 8% market share in the field-targeted universe versus ~1% in non-targeted. Commercial coverage is 90%. Q2 operating expenses were $95.1M. ARS expects cash-flow breakeven by end-2027 and Phase IIb CSU interim data in Q1 2027.

yahoo.com6 min
AUG 13
$SPRYMed

ARS Pharmaceuticals, Inc. (SPRY): Results of Operations and Financial Condition

ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5%

SEC EDGAR 8-K7 min
JUL 15
$SPRYMed

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

ARS Pharmaceuticals (NASDAQ:SPRY) said CEO Richard Lowenthal will stop working for the company, effective July 6. Donn Casale, then President, was appointed CEO and Director, taking over July 7. The company also reported payer access updates for neffy, noting no new coverage decisions in the July 1 cycle and continued availability via direct coverage and a retail cash option.

yahoo.com4 min